A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis

Cell Death and Disease

Volumn 6, Issue 5, 2015, Pages

  Fauster, A ^a   Rebsamen, M ^a   Huber, K V M ^a   Bigenzahn, J W ^a   Stukalov, A ^a,c   Lardeau, C H ^a   Scorzoni, S ^a   Bruckner, M ^a   Gridling, M ^a   Parapatics, K ^a   Colinge, J ^a   Bennett, K L ^a   Kubicek, S ^a   Krautwald, S ^b   Linkermann, A ^b   Superti Furga, G ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b UNIVERSITY OF KIEL   (Germany)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MIXED LINEAGE KINASE; PAZOPANIB; PONATINIB; PROTEIN; RIPK1 PROTEIN; RIPK3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FADD PROTEIN, HUMAN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMIDAZOLE DERIVATIVE; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MLKL PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK1 PROTEIN, HUMAN; RIPK3 PROTEIN, HUMAN; SULFONAMIDE; TUMOR NECROSIS FACTOR;

3T3 CELL LINE; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG PROTEIN BINDING; EMBRYO; ENZYME PHOSPHORYLATION; GENE TARGETING; HEK293 CELL LINE; HUMAN; HUMAN CELL; KINASE ASSAY; L929 CELL LINE; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; HT-29 CELL LINE; JURKAT CELL LINE; L CELL LINE; METABOLISM; MOUSE; NECROSIS; PHOSPHORYLATION; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HEK293 CELLS; HT29 CELLS; HUMANS; IMIDAZOLES; JURKAT CELLS; L CELLS (CELL LINE); MAP KINASE KINASE KINASES; MICE; NECROSIS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDAZINES; PYRIMIDINES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84956475487     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.130     Document Type: Article

References (69)

1. Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell 2011; 147: 742-758.
2. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517: 311-320.
3. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014; 370: 455-465.
4. Chan FK-M, Luz NF, Moriwaki K. Programmed Necrosis in the Cross Talk of Cell Death and Inflammation. Annu Rev Immunol 2014; 33: 141210135520002.
5. Christofferson DE, Li Y, Yuan J. Control of Life-or-Death Decisions by RIP1 Kinase. Annu Rev Physiol 2014; 76: 129-150.
6. Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta 2013; 1833: 3448-3459.
7. Upton JW, Kaiser WJ, Mocarski ES. Virus Inhibition of RIP3-dependent necrosis. Cell Host Microbe 2010; 7: 302-313.
8. Mocarski ES, Upton JW, Kaiser WJ. Viral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathways. Nat Rev Immunol 2011; 12: 79-88.
9. Humphries F, Yang S, Wang B, Moynagh PN. RIP kinases: key decision makers in cell death and innate immunity. Cell Death Differ 2014; 22: 225-236.
10. Linkermann A, Stockwell BR, Krautwald S, Anders H-J. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 2014; 14: 759-767.
11. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-495.
12. Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ et al. Toll-like Receptor 3-mediated Necrosis via TRIF, RIP3, and MLKL. J Biol Chem 2013; 288: 31268-31279.
13. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
14. Upton Jason W, Kaiser William J, Mocarski Edward S. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 2012; 11: 290-297.
15. Thapa RJ, Nogusa S, Chen P, Maki JL, Lerro A, Andrake M et al. Interferon-induced RIP1/ RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc Natl Acad Sci USA 2013; 110: E3109-E3118.
16. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313-321.
17. He S, Liang Y, Shao F, Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc Natl Acad Sci USA. 2011; 108: 20054-20059.
18. Cho Y, Challa S, Moquin D, Genga R, Ray TD, Guildford M et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112-1123.
19. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell 2009; 137: 1100-1111.
20. Galluzzi L, Vanden Berghe T, Vanlangenakker N, Buettner S, Eisenberg T, Vandenabeele P et al. Programmed necrosis from molecules to health and disease. Int Rev Cell Mol Biol 2011; 289: 1-35.
21. Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domainlike protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
22. Wang H, Sun L, Su L, Rizo J, Liu L, Wang L-F et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 2014; 54: 133-146.
23. Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 2014; 7: 971-981.
24. Su L, Quade B, Wang H, Sun L, Wang X, Rizo J. A plug release mechanism for membrane permeation by MLKL. Structure 2014; 22: 1489-1500.
25. Cai Z, Jitkaew S, Zhao J, Chiang H-C, Choksi S, Liu J et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 2013; 16: 55-65.
26. Chen X, Li W, Ren J, Huang D, He W-t, Song Y et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res 2013; 24: 105-121.
27. Kaczmarek A, Vandenabeele P, Krysko Dmitri V. Necroptosis: the release of damageassociated molecular patterns and its physiological relevance. Immunity 2013; 38: 209-223.
28. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
29. Lin J, Li H, Yang M, Ren J, Huang Z, Han F et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep 2013; 3: 200-210.
30. Murakami Y, Matsumoto H, Roh M, Giani A, Kataoka K, Morizane Y et al. Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsRNA-induced retinal degeneration. Cell Death Differ 2013; 21: 270-277.
31. Linkermann A, Brasen JH, Darding M, Jin MK, Sanz AB, Heller JO et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA 2013; 110: 12024-12029.
32. Oerlemans MIFJ Liu J, Arslan F, Ouden K, Middelaar BJ, Doevendans PA et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia- reperfusion in vivo. Basic Res Cardiol 2012; 107: 270.
33. Lau A, Wang S, Jiang J, Haig A, Pavlosky A, Linkermann A et al. RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am J Transplant 2013; 13: 2805-2818.
34. Hildebrand JM, Tanzer MC, Lucet IS, Young SN, Spall SK, Sharma P et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad Sci USA 2014; 111: 15072-15077.
35. Harris PA, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti CA, Cox JA et al. Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis. ACS Med Chem Lett 2013; 4: 1238-1243.
36. Juo P, Woo MS, Kuo CJ, Signorelli P, Biemann HP, Hannun YA et al. FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ 1999; 10: 797-804.
37. Lawrence CP, Chow SC. FADD deficiency sensitises Jurkat T cells to TNF-α-dependent necrosis during activation-induced cell death. FEBS Lett 2005; 579: 6465-6472.
38. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a Pan- BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.
39. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al. Ponatinib in refractory philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075-2088.
40. Ward JE, Stadler WM. Pazopanib in renal cell carcinoma. Clin Cancer Res 2010; 16: 5923-5927.
41. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2012; 379: 1879-1886.
42. Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG et al. Discovery of 5- [[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008; 51: 4632-4640.
43. Teng X, Degterev A, Jagtap P, Xing X, Choi S, Denu R et al. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett 2005; 15: 5039-5044.
44. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513-526.
45. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615-619.
46. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2008; 23: 477-485.
47. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655.
48. Vince JE, WW-L Wong, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 2007; 131: 682-693.
49. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009; 5: 616-624.
50. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046-1051.
51. Huber KVM, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 2014; 508: 222-227.
52. Morioka S, Broglie P, Omori E, Ikeda Y, Takaesu G, Matsumoto K et al. TAK1 kinase switches cell fate from apoptosis to necrosis following TNF stimulation. J Cell Biol 2014; 204: 607-623.
53. Mihaly SR, Ninomiya-Tsuji J, Morioka S. TAK1 control of cell death. Cell Death Differ 2014; 21: 1667-1676.
54. Li J, McQuade T, Siemer Ansgar B, Napetschnig J, Moriwaki K, Hsiao Y-S et al. The RIP1/ RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 2012; 150: 339-350.
55. Molina DM, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 2013; 341: 84-87.
56. Li JX, Feng JM, Wang Y, Li XH, Chen XX, Su Y et al. The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis 2014; 5: e1278.
57. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009; 15: 4220-4227.
58. Hutson TE, Davis ID, Machiels JPH, De Souza PL, Rottey S, Bf Hong et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 28: 475-480.
59. Kaiser WJ, Daley-Bauer LP, Thapa RJ, Mandal P, Berger SB, Huang C et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc Natl Acad Sci USA 2014; 111: 7753-7758.
60. Mandal P, Berger Scott B, Pillay S, Moriwaki K, Huang C, Guo H et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell 2014; 56: 481-495.
61. Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014; 343: 1357-1360.
62. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783-1796.
63. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III Trial. J Clin Oncol 2010; 28: 1061-1068.
64. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283-13288.
65. Linkermann A, Hackl MJ, Kunzendorf U, Walczak H, Krautwald S, Jevnikar AM. Necroptosis in immunity and ischemia-reperfusion injury. Am J Transplant 2013; 13: 2797-2804.
66. Rebsamen M, Heinz LX, Meylan E, Michallet M-C, Schroder K, Hofmann K et al. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-κB. EMBO Rep 2009; 10: 916-922.
67. Zuber J, Rappaport AR, Luo W,Wang E, Chen C, Vaseva AV et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 2011; 25: 1628-1640.
68. Rebsamen M, Pochini L, Stasyk T, de Araujo ME, Galluccio M, Kandasamy RK et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 2015; 519: 477-81.
69. Lavallee-Adam M, Cloutier P, Coulombe B, Blanchette M. Modeling contaminants in AP-MS/ MS experiments. J Proteome Res 2011; 10: 886-895.